US Stocks Mixed; Wholesale Inventories Increase 1.3% In August
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 20 points on Wednesday.
RBC Capital Maintains Outperform on Prothena Corp, Raises Price Target to $52
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Outperform and raises the price target from $45 to $52.
Prothena Corp Q2 EPS $(0.88) Misses $(0.52) Estimate, Sales $1.31M Miss $17.17M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.52) by 69.23 percent. This is a 251.72 percent decrease over earnings of $0.58 per share from
Jim Cramer Says This Company Is A Great One
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Woodside Energy Group Ltd (NYSE: WDS) is a great company, with a great yield.
JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $50
JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price target from $77 to $50.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
A Preview Of Prothena Corp’s Earnings
Prothena Corp (NASDAQ:PRTA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Prothena Corp will report an earnings per share (EPS) of $-0.68.
Why RBC Capital Sees ‘Multiple High-Risk’ On This Neurology-Focused Stock
RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the space could drive appreciation.
Prothena Receives FDA Fast Track Designation for PRX012 for the Treatment of Alzheimer’s Disease
Prothena Corporation plc (NASDAQ: PRTA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-amyloid beta (Aβ) antibody therapy drug candidate PRX012 for the treatment of Alzheimer's disease.